SCHEMBL2679362

SCHEMBL2679362

Cc1ccc(NC(=O)c2ccc(C)c(NC(=O)C=Cc3cccnc3)c2)cc1Br

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.56
MAPT P10636 2/20 0.56
KMT2A Q03164 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
MEN1 O00255 1/20 0.56
GALR2 O43603 1/20 0.56
HPGD P15428 1/20 0.56
RECQL P46063 1/20 0.56
HDAC1 Q13547 2/20 0.54
HDAC3 O15379 1/20 0.54
ABL1 P00519 1/20 0.54
PDGFRB P09619 1/20 0.54
BCR P11274 1/20 0.54
KDR P35968 1/20 0.54
HDAC4 P56524 1/20 0.54
HDAC7 Q8WUI4 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10054900 0.96 HDAC1 (0.56) LMNAMAPTKMT2ACYP1A2CYP3A4
SCHEMBL2680451 0.89 LCK (0.48) LMNAMAPTKMT2ACYP1A2CYP3A4
SCHEMBL10077752 0.89 LMNA (0.64) LMNAMAPTKMT2ACYP1A2CYP3A4
SCHEMBL2679317 0.89 LMNA (0.64) LMNAMAPTKMT2ACYP1A2CYP3A4
SCHEMBL10078409 0.89 NAMPT (0.63) LMNAMAPTKMT2ACYP1A2CYP3A4
SCHEMBL2680476 0.89 NAMPT (0.63) LMNAMAPTKMT2ACYP1A2CYP3A4
SCHEMBL2679216 0.88 NAMPT (0.57) LMNAMAPTKMT2ACYP1A2CYP3A4
SCHEMBL10078412 0.88 NAMPT (0.57) LMNAMAPTKMT2ACYP1A2CYP3A4
SCHEMBL10077687 0.87 NAMPT (0.64) LMNAMAPTKMT2ACYP1A2CYP3A4
SCHEMBL2679261 0.87 NAMPT (0.64) LMNAMAPTKMT2ACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US claimed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US claimed
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US disclosed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament ABL1, ABL2, BCR LMNA 4558/4885MAPT 1476/4885KMT2A 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.